Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP267630.RA2CJI3CMcc1C82ODYwl-Dgh47QVia6TabF_DQpG94rMA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP267630.RA2CJI3CMcc1C82ODYwl-Dgh47QVia6TabF_DQpG94rMA130_assertion type Assertion NP267630.RA2CJI3CMcc1C82ODYwl-Dgh47QVia6TabF_DQpG94rMA130_head.
- NP267630.RA2CJI3CMcc1C82ODYwl-Dgh47QVia6TabF_DQpG94rMA130_assertion description "[The low cancer incidence in the epididymis may be due to factors present in the human epididymis that regulate this oncogenic Wnt/?-catenin pathway, including (i) 14 of 17 secreted pathway inhibitors, (ii) the majority of the micro-RNAs known to target this pathway, (iii) plasma membrane-associated E-cadherin and CEACAM1 that anchor ?-catenin, preventing its availability for nuclear entry and oncogenic transcriptional activity, (iv) the recently identified membrane-located tumourigenesis inhibitors RNF43 and ZNRF3 that mediate the degradation of the Wnt receptor components Fzds and Lrp5/6 and (v) nuclear KLF4, which competes with TCF for ?-catenin, limiting its transcriptional activity and stabilizing telomeres, thereby reducing mutation incidence.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP267630.RA2CJI3CMcc1C82ODYwl-Dgh47QVia6TabF_DQpG94rMA130_provenance.
- NP267630.RA2CJI3CMcc1C82ODYwl-Dgh47QVia6TabF_DQpG94rMA130_assertion evidence source_evidence_literature NP267630.RA2CJI3CMcc1C82ODYwl-Dgh47QVia6TabF_DQpG94rMA130_provenance.
- NP267630.RA2CJI3CMcc1C82ODYwl-Dgh47QVia6TabF_DQpG94rMA130_assertion SIO_000772 23155044 NP267630.RA2CJI3CMcc1C82ODYwl-Dgh47QVia6TabF_DQpG94rMA130_provenance.
- NP267630.RA2CJI3CMcc1C82ODYwl-Dgh47QVia6TabF_DQpG94rMA130_assertion wasDerivedFrom befree-20150227 NP267630.RA2CJI3CMcc1C82ODYwl-Dgh47QVia6TabF_DQpG94rMA130_provenance.
- NP267630.RA2CJI3CMcc1C82ODYwl-Dgh47QVia6TabF_DQpG94rMA130_assertion wasGeneratedBy ECO_0000203 NP267630.RA2CJI3CMcc1C82ODYwl-Dgh47QVia6TabF_DQpG94rMA130_provenance.